These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8410074)

  • 21. [Autoantibodies in myasthenia gravis].
    Motomura M; Narita Masuda T
    Brain Nerve; 2013 Apr; 65(4):433-9. PubMed ID: 23568991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Future therapeutic strategies in autoimmune myasthenia gravis.
    Psaridi-Linardaki L; Mamalaki A; Tzartos SJ
    Ann N Y Acad Sci; 2003 Sep; 998():539-48. PubMed ID: 14592926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro quantitative autoradiography of [125I]alpha-bungarotoxin binding at the motor end-plates of experimental autoimmune myasthenia gravis.
    Motomura M; Niwa M; Kataoka Y; Ootsuru I; Yoshimura T; Tsujihata M; Nagataki S
    Neurosci Lett; 1992 Aug; 143(1-2):139-42. PubMed ID: 1436658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors.
    Almon RR; Andrew CG; Appel SH
    Science; 1974 Oct; 186(4158):55-7. PubMed ID: 4421998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myasthenia gravis as a prototype autoimmune receptor disease.
    Hoedemaekers AC; van Breda Vriesman PJ; De Baets MH
    Immunol Res; 1997; 16(4):341-54. PubMed ID: 9439759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J; Wang ZY; Link H
    J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of human-Torpedo hybrid acetylcholine receptor (AChR) for analysing the subunit specificity of antibodies in sera from patients with myasthenia gravis (MG).
    Loutrari H; Kokla A; Trakas N; Tzartos SJ
    Clin Exp Immunol; 1997 Sep; 109(3):538-46. PubMed ID: 9328134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-bungarotoxin blocking antibodies in neonatal myasthenia gravis: frequency and selectivity.
    Vernet-der Garabedian B; Eymard B; Bach JF; Morel E
    J Neuroimmunol; 1989 Jan; 21(1):41-7. PubMed ID: 2908881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.
    Tzartos SJ; Cung MT; Demange P; Loutrari H; Mamalaki A; Marraud M; Papadouli I; Sakarellos C; Tsikaris V
    Mol Neurobiol; 1991; 5(1):1-29. PubMed ID: 1725702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis.
    Mittag T; Massa T; Kornfeld P; Papatestas A; Bender A; Genkins G
    Muscle Nerve; 1981; 4(1):16-25. PubMed ID: 6164920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myasthenic sera recognize the human acetylcholine receptor bound to thymopoietin.
    Morel E; Vernet-der Garabedian B; Raimond F; Audhya TK; Goldstein G; Bach JF
    Eur J Immunol; 1987 Aug; 17(8):1109-13. PubMed ID: 3622601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro.
    Burges J; Wray DW; Pizzighella S; Hall Z; Vincent A
    Muscle Nerve; 1990 May; 13(5):407-13. PubMed ID: 2345558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-ligand antibodies as potential autoantigens: in vitro and in vivo characteristics of anti-bungarotoxin antibodies in the idiotype network.
    Pachner AR; Itano AA; McCallum RM; Ricalton NS
    Autoimmunity; 1991; 10(2):145-52. PubMed ID: 1782327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunochemical properties of junctional and extrajunctional acetylcholine receptor.
    Dwyer DS; Bradley RJ; Furner RL; Kemp GE
    Brain Res; 1981 Jul; 217(1):23-40. PubMed ID: 6167329
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of human skeletal muscle acetylcholine receptor antibodies using monkey receptors.
    Mickle DA; Wong PY; Humphrey JG; Griffith K; Mee AV
    Clin Biochem; 1983 Jun; 16(3):163-6. PubMed ID: 6851078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A non-immunogenic myasthenia gravis model and its application in a study of transsynaptic regulation at the neuromuscular junction.
    Molenaar PC; Oen BS; Plomp JJ; Van Kempen GT; Jennekens FG; Hesselmans LF
    Eur J Pharmacol; 1991 Apr; 196(1):93-101. PubMed ID: 1874282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Heterogeneity of acetylcholine receptor antibodies in patients with myasthenia gravis].
    Kalies I; Heinz F; Kaschka WP; Druschky KF; Kalden JR
    Klin Wochenschr; 1984 Apr; 62(8):377-85. PubMed ID: 6727277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoclonal anti-acetylcholine receptor antibodies as probes for human acetylcholine-receptor in myasthenia gravis.
    Vincent A; Whiting PJ; Heidenreich F; Roberts A
    J Recept Res; 1988; 8(1-4):143-59. PubMed ID: 3260283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.